Milestone Pharmaceuticals Inc.近日宣布，其研发的Cardamyst™（Etripamil）鼻喷雾剂已正式在美国市场推出。该药物是美国食品药品监督管理局（FDA）批准的首个且唯一一款可由成人阵发性室上性心动过速患者自行给药的疗法。
Milestone Pharmaceuticals Inc.近日宣布，其研发的Cardamyst™（Etripamil）鼻喷雾剂已正式在美国市场推出。该药物是美国食品药品监督管理局（FDA）批准的首个且唯一一款可由成人阵发性室上性心动过速患者自行给药的疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.